Year All 2026 2025 2024 2023 2022 2019 Date Title Download October 23, 2026 AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) October 21, 2026 AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms October 20, 2026 AN2 Therapeutics to Participate at Upcoming Investor Conferences September 28, 2026 AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK September 16, 2026 AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) August 31, 2026 AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting August 24, 2026 AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer August 11, 2026 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights June 4, 2026 AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease May 21, 2026 AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference